Prof. Pierre Amarenco, Paris, France in discussion with prof
John Kastelein on the importance of
lipid management in the prevention of stroke
|
|
|
|
INTERSTROKE:
|
|
|
|
Meta-analysis : Statin and Stroke
|
|
|
|
Meta-Analysis Stroke Death
|
|
|
|
Meta-analysis Hemorrhagic stroke
|
|
|
|
Stroke Risk and LDL Lowering
|
|
|
|
JUPITER
|
|
|
|
Secondary End Point:
|
|
|
|
CARDS:Cumulative Hazard for Stroke
|
|
|
|
Pleiotropic Effects
|
|
|
|
|
|
|
Primary and Secondary Endpoints
|
|
|
|
Stroke:Potential Mechanisms of Benefit
|
|
|
|
HPS: No Reduction in Risk of Recurrent Stroke
|
|
|
|
SPARCL: Study Design
|
|
|
|
LCL-C During Follow-up
|
|
|
|
|
|
|
Gender: Stroke Outcomes
|
|
|
|
SPARCL Elderly vs Young
|
|
|
|
SPARCL Elderly vs Young
|
|
|
|
|
|
|
|
|
Impact of Atorvastatin on Stroke Risk
|
|
|
|
Impact of Atorvastatin on Coronary Risk and Death
|
|
|
|
Benefit/Risk
|
|
|
|
Ischemic Stroke Severity
|
|
|
|
Effect of Atorvastatin on Stroke In SPARCL
|
|
|
|
|
|
Effect of Atorvastatin on Renal Function by Glycemic Status
|
|
|
|
Stroke in Patients With Carotid Stenosis
|
|
|
|
|
|
|
Stroke Risk and LDL Lowering
|
|
|
|
Stroke Risk and LDL Lowering
|
|
|
|
Time Varying LDL-C and Stroke Risk
|
|
|
|
Time Varying LDL-C and Stroke Risk
|
|
|
|
|
|
|
|
Optimal Multi-Targets
|
|
|
Addressing the stroke crisis in Asia (PPT 2.5MB)
Share this page with your colleagues and friends: